GLP-1 provides powerful appetite suppression and gastric slowing
Obesity is so common that the CDC now considers it to be a national epidemic
No human trial has tracked use beyond about 12 weeks, so timelines within that window are based on preclinical data, and individual results vary by injury type and severity
However, studies also showed GLP-1 agonists can cause vision changes, including blurred vision, worsening of diabetic retinopathy and macular complications
After 17 weeks of open label therapy, subjects who maintained at least a PASI 75 response at Week 33 and were originally randomized to active therapy in period A were re-randomized in period C to receive 40 mg HUMIRA every other week or placebo for an additional 19 weeks
Delivery systems vary pens, prefilled syringes, and refrigeration needs affect portability